Italia markets close in 6 hours 37 minutes

MYGN May 2024 14.000 put

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
0,84000,0000 (0,00%)
In data: 02:39PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente0,8400
ApertoN/D
Denaro0,1500
Lettera0,3000
Prezzo d'esercizio14,00
Scadenza2024-05-17
Min-Max giorno0,8400 - 0,8400
Contratto - Min-MaxN/D
VolumeN/D
Open Interest2
  • GlobeNewswire

    New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

    SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey revealing breast density and family health history are two misunderstood breast cancer risk factors. The Myriad Genetics Cancer Risk Survey found that nearly half (48%) of the women surveyed do not know what breast density is, and 50% are unsure if breast density has anything to do with breast cancer risk. Wo

  • GlobeNewswire

    Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

    Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera

  • GlobeNewswire

    Myriad Genetics Issues 2022 Environmental, Social and Governance Report

    SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report, highlighting key efforts that reflect its commitment to conduct operations as a responsible, equitable and sustainable partner in the healthcare industry. “At Myriad, we understand the important role we play in advancing health equity and social justice,” said Paul Diaz, presiden